NCT02041117

Resuvastatin Treatment for Symptomatic Middle Cerebral Artery Stenosis Based on High-resolution Magnetic Resonance Imaging

Resuvastatin Treatment for Symptomatic Middle Cerebral Artery Stenosis Based on High-resolution Magnetic Resonance Imaging in Two Years

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 162 (actual)
• Sponsor: Beijing Tiantan Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

1. It is a multicenter, open-label, sing arm study to evaluate the effects of treatment of Rosuvastatin 10-20mg in volume and morphology of atherosclerotic plague by reducing LDL-C level to or less than 70mg/dl. 2. Ischemic stroke patients will be enrolled within 1 month after stroke onset. 3. Patients will be visited at 0m, 1m, 3m, 6m, 9m, 12m, 18m and 24m.

Conditions

• Intracranial Arterial Stenosis

Interventions

Type	Name	Description
DRUG	Rosuvastatin	Rosuvastatin, 10mg for 4-weeks, then according to the results of the LDL-C, adjust dose of rosuvastatin, maximum to 20 mg/d, to reduce LDL-C under 70 mg/dl for two years.

Timeline

• Start date: 2014-02-24
• Primary completion: 2018-11-06
• Completion: 2018-11-06
• First posted: 2014-01-20
• Last updated: 2020-07-27

Locations

1 site across 1 country: China